Free Trial

AIkido Pharma (AIKI) Stock Price, News & Analysis

+0.01 (+0.27%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
7,736 shs
Average Volume
79,326 shs
Market Capitalization
$11.74 million
P/E Ratio
Dividend Yield
Price Target
AIKI stock logo

About AIkido Pharma Stock (NASDAQ:AIKI)

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

AIKI Stock Price History

AIKI Stock News Headlines

SNOA Sonoma Pharmaceuticals, Inc.
Royalty Pharma PLC
Dominari Holdings Inc. Releases Shareholder Update
Kyle Wool Appears on Fox Business
Dominari Holdings Appoints George Way As CFO
Dominari Holdings Provides Business Update
AIkido Share Repurchase Continues
AIkido Purchases More Shares
Share Repurchase Program Continues
AIkido Pharma Continues Share Repurchase Program
AIkido Pharma Provides Update on Share Repurchase Program
AIkido Pharma Confirms Receipt of Unsolicited Offer
Aikido Pharma Inc
See More Headlines
Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$19.27 per share


Free Float
Market Cap
$11.74 million
Not Optionable

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Anthony C. Hayes Esq. (Age 54)
    CEO, Principal Financial Officer, Principal Accounting Officer & Director
    Comp: $960k
  • Mr. Darrell Dotson
    VP of Drug Devel. & Gen. Counsel
  • Mr. Carlos Aldavero
    Pres of Dominari Financial

AIKI Stock Analysis - Frequently Asked Questions

How have AIKI shares performed in 2024?

AIkido Pharma's stock was trading at $2.59 at the beginning of 2024. Since then, AIKI shares have decreased by 17.4% and is now trading at $2.1399.
View the best growth stocks for 2024 here

When did AIkido Pharma's stock split?

Shares of AIkido Pharma reverse split on Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of AIkido Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), Nuwellis (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV).

How do I buy shares of AIkido Pharma?

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AIkido Pharma have any subsidiaries?
The following companies are subsidiares of AIkido Pharma: Hoth Therapeutics.
Read More
This page (NASDAQ:AIKI) was last updated on 5/22/2024 by Staff

From Our Partners